CAV-2 Vector Delivery of SCN1A for Neuronal Nav1.1 Expression
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy approaches for Dravet syndrome (DS) face challenges due to the large size of the SCN1A ORF, limited vector capacity, and safety concerns with existing vectors like AAV and HAdV, which fail to effectively target neuronal cells and provide long-term expression, especially in severe DS cases.
Innovation Solution
Utilizing a canine adenovirus type 2 (CAV-2) vector to deliver an SCN1A expression cassette, which has a 35 kbp cloning capacity, preferentially targets neurons through the coxsackievirus and adenovirus receptor, and enables controlled expression in various neuronal populations, providing exogenous Nav1.1 channels to compensate for the loss-of-function mutations.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If AAV or HAdV vectors are used to deliver SCN1A, then gene delivery is attempted, but the vector capacity is insufficient and neuronal targeting is inadequate
Solution Approach 1:
The CAV-2 vector system provides multi-functionality by combining large packaging capacity (35 kbp) with specific neuronal targeting capability through the Coxsackie and Adenovirus Receptor (CAR), making it suitable for delivering large genes like SCN1A specifically to neuronal cells
Solution Approach 2:
The patent uses the CAR receptor as an intermediary to achieve selective neuronal targeting. The CAV-2 vector binds to CAR on neuronal surfaces, enabling specific delivery of the SCN1A gene to neuronal cells while leaving other cell types unaffected
2Duration of action of stationary object
If conventional vectors are used, then delivery is attempted, but long-term expression is not achieved
Solution Approach 1:
The patent employs inducible promoters (tetracycline-responsive or doxycycline-responsive) that allow dynamic control of SCN1A expression. Expression can be turned on or off based on doxycycline presence, enabling long-term stable expression when needed while providing control when necessary
3Quantity of substance
If large SCN1A ORF is delivered, then gene replacement is attempted, but existing vectors lack sufficient cloning capacity
Solution Approach 1:
The patent changes the key parameter of vector packaging capacity by using CAV-2 vectors that can accommodate up to 35 kbp of foreign DNA, compared to the limited capacity of AAV or HAdV vectors. This parameter change enables successful delivery of the large SCN1A ORF
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The CAV-2 vector effectively reduces epilepsy and improves survival in adolescent mice with severe DS, reducing spontaneous seizures and febrile seizure thresholds, and shows potential for treating DS comorbidities and other Nav1.1-associated conditions.
Implementation Method 1
preferentially targets neurons through the coxsackievirus and adenovirus receptor
Data Source
AI summary
A method for use in the treatment of diseases affecting the brain by providing exogenous Nav1.1 via CAV-2 vector-mediated delivery of a copy of SCNIA ORF into central nervous system (CNS) neurons. The method includes injection of the viral vector into the hippocampus and/or thalamus. Transcriptional control of the SCNIA expression cassette can be provided by specific promoters, such as NSE, to achieve targeted neuronal expression. This strategy is suitable as a therapeutic approach regardless of the underling SCNIA mutation. Moreover, because this approach compensates for the loss of function of Nav1.1, it can potentially ameliorate Dravet Syndrome, epileptic and non-epileptic comorbidities thereof, epilepsy, Alzheñner's, and other Nav1.1-associated pathological conditions.